Haleon (LON:HLN) Given Buy Rating at Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of Haleon (LON:HLN) in a research report report published on Wednesday morning, MarketBeat Ratings reports. Jefferies Financial Group currently has a GBX 450 target price on the stock.

HLN has been the subject of a number of other reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a report on Friday, October 31st. JPMorgan Chase & Co. raised their price target on shares of Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research report on Wednesday, November 26th. Finally, Berenberg Bank lifted their price target on Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of GBX 422.40.

Haleon Price Performance

Haleon stock opened at GBX 378.77 on Wednesday. The stock has a fifty day moving average of GBX 368.53 and a 200-day moving average of GBX 359.19. Haleon has a 52 week low of GBX 325.10 and a 52 week high of GBX 419.50. The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84. The stock has a market capitalization of £33.73 billion, a P/E ratio of 22.68, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.